IBRX has been in the news 900% more than usual
Feb 19, 2026, 5:37 PM
23.38%
What does IBRX do
ImmunityBio is a San Diego-based clinical stage immunotherapy company with 628 employees, focusing on therapies for urologic cancers and infectious diseases. Its lead product candidate, Anktiva, is an IL-15 superagonist fusion protein.
IBRX has been in the news recently: European Commission authorization has allowed ImmunityBio to establish a commercial footprint across four jurisdictions in under two years, and its drug ANKTIVA has been cleared for two indications in Saudi Arabia. ImmunityBio Inc. (NASDAQ: IBRX) shows a confirmed Golden Cross and is trading about 170% above its 200‑day moving average, indicating a strong long-term uptrend.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.